Safety and patient-reported outcomes in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors in China: A cross-sectional study.

This cross-sectional study in China involving 1254 patients with hormone receptor-positive, HER2-negative advanced breast cancer assessed the safety and patient-reported outcomes of different CDK4/6 inhibitors. Dalpiciclib was found to have the lowest incidence of adverse events such as increased ALT, AST, and diarrhea compared to other inhibitors. Patients reported fewer issues with fatigue, alopecia, and other side effects when using dalpiciclib. Quality of life assessments indicated that hair loss was a significant concern, but dalpiciclib users were the least upset by it, particularly those treated for over 6 months. Overall, dalpiciclib demonstrated the best safety profile and patient satisfaction among the CDK4/6 inhibitors studied.